Jennifer Cavan

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

Abstract: Background: In the 5-week, randomized, double-blind, placebo-controlled, phase 2 EMERGENT-1 study (NCT03697252), the M1/M4 preferring muscarinic receptor agonist KarXT met prima...

Christoph U. Correll , MD;

Jennifer Cavan ;

01/26/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Jennifer Cavan

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products